European Society of Cutaneous Lupus Erythematosus (EUSCLE)

NCT ID: NCT00420121

Last Updated: 2017-02-08

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 300 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2019-12-31

Brief Summary

Cutaneous lupus erythematosus (CLE) is a disease with a wide spectrum of clinical manifestations and a variable prognosis. The aim of the study is to create a standardized evaluation of the different subtypes of this disease in order to receive an overview of the spectrum of clinical and laboratory features as well as the therapeutic strategies for patients with CLE.

Detailed Description

Methods: A core set questionnaire has been developed in the course of the "European Society of Cutaneous Lupus Erythematosus (EUSCLE)", and a total of 40 patients (32 females, 8 males) in two centres, Germany and Sweden, were included in this study. Results: CLE was diagnosed in 39 individuals (5 with acute CLE, 10 with subacute CLE, 13 with chronic CLE, and 18 with intermittent CLE) and one individual presented with a systemic manifestation of the disease. Furthermore, disease onset and duration as well as activity and damage of skin lesions using a modified CLASI were examined. Interestingly, 75% of the patients with CLE showed a positive history of photosensitivity, but only 62.5% exhibited characteristic lesions after standardized phototesting. Laboratory analysis revealed positive antinuclear antibodies in 50% of the patients, positive anti-Ro/SSA in 12 and positive anti-La/SSB antibodies in 8 cases. The predominantly used treatments included sunscreens (38 patients), topical steroids (31 patients), topical calcineurin inhibitors (12 patients), chloroquine (19 patients), hydroxychloroquine (11 patients), and systemic steroids (12 patients). Conclusions: The new core set questionnaire enables the clinician to characterize the different skin manifestations involved in CLE and to evaluate disease activity and reasonable treatment modalities. Furthermore, epidemiological data and laboratory features can be assessed for the various subtypes. In the future, this standardized evaluation might lead to the development of diagnostic guidelines and evidence based therapeutic strategies thus improving quality of care for patients with CLE.

Conditions

Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Interventions

laboratory analysis

blood withdrawal for laboratory analysis

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• systemic or cutaneous lupus erythematosus confirmed by histological analysis
• written informed consent available prior to any study-procedures

Exclusion Criteria

• patients with conditions that are contrary to the above mentioned criteria

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

European Society of Cutaneous Lupus Erythematosus e.V.

OTHER

Sponsor Role: lead

Responsible Party

Prof. Dr. Annegret Kuhn

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Annegret Kuhn, MD

Role: PRINCIPAL_INVESTIGATOR

University of Muenster, Department of Dermatology

Locations

University of Muenster, Department of Dermatology

Münster, North Rhine-Westphalia, Germany

Countries

Germany

Other Identifiers

2742-2

Identifier Type: -

Identifier Source: org_study_id